MHE October 2025
Site neutrality payment, innovations in care delivery and value-based pricing of drugs could at least help to moderate the huge growth in expenditures.
Novo Nordisk has a factor VIII mimetic in a phase 3 trial, and a Chinese company is forging ahead with its gene therapy product.
At first, it was tentative. But now almost all parts of the U.S. healthcare system are racing to adopt some form of artificial intelligence. Some leaders caution about using it too widely, too fast.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Gene therapy in the real world: High priced, a long process and still relatively few patients | ASH 2025
2
IV iron treatment improves survival, increases hemoglobin levels in anemic patients with acute bacterial infection | ASH 2025
3
Jaypirca shows promise as a frontline treatment for CLL/SLL patients | ASH 2025
4
Positive results for Casgevy but with one patient death from myeloablative busulfan conditioning | ASH 2025
5
